Dr. Rustam Esanov received his PhD in Molecular and Cellular Pharmacology from University of Miami, where he studied epigenetic abnormalities in Amyotrophic Lateral Sclerosis using induced pluripotent stem cells. After completing his PhD, he joined Kristin Baldwin’s lab at The Scripps Research Institute to study Friedreich’s Ataxia by utilizing patient-derived induced sensory neurons. He then transitioned to industry and joined Nuredis Inc., where he led the development of cell-based drug screening assays for Huntington’s Disease and Myotonic Dystrophy. He also worked on development of novel long-lasting neuromodulators at Revance Therapeutics and small molecule drug discovery for Parkinson’s Disease at Nitrome Biosciences. Rustam joined LGR as an Investigator for GSK in 2021.